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Abstract 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor 
neurons. To date, more than 20 genes have been implicated in ALS, and of these, the two most 
frequently mutated are the superoxide dismutase 1 (SOD1) gene and the chromosome 9 open reading 
frame 72 (C9ORF72) gene. In this study, we aimed to investigate the contribution of these two 
Mendelian genes to the development of the disease in Hungarian ALS patients (n=66). Direct sequencing 
of the SOD1 gene revealed a novel (p.Lys91ArgfsTer8) and three recurrent heterozygous mutations 
(p.Val14Met, p.Asp90Ala, p.Leu144Phe) in five patients. The novel p.Lys91ArgfsTer8 mutation led to a 
frameshift causing the addition of eight new amino acids, including a premature stop codon at position 
99. The GGGGCC hexanucleotide repeat expansion of the C9ORF72 gene was present in one ALS patient. 
This study represents the first genetic analysis of two major ALS causative genes in a cohort of Hungarian 
ALS patients and contributes to the further understanding of the genetic and phenotypic diversity of ALS. 
Key words: ALS, SOD1, C9ORF72, mutation screening, repeat expansion 
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1. Introduction  
 
Amyotrophic lateral sclerosis (ALS; ORPHA803), also known as ”Lou Gehrig’s disease”, is a fatal, 
neurodegenerative disorder characterized by the death of motor neurons in the brain, brainstem and 
spinal cord, resulting in fatal paralysis (Morrison and Harding, 1994). Familial forms account for about 
10% of ALS cases, while other cases are sporadic (Strong et al., 1991; Hewitt et al., 2010). Familial forms 
are mainly transmitted in a Mendelian pattern of autosomal dominant inheritance (Hardiman et al., 
2011). Regarding its genetic background, more than 20 genes have been implicated in the development 
of ALS (ALSoD Database, http://alsod.iop.kcl.ac.uk).  
Among the ALS causative genes, superoxide dismutase 1 (SOD1) is one of the most commonly mutated 
genes and accounts for approximately 12–23% of the familial and up to 7% of the sporadic ALS forms 
(Andersen, 2006). SOD1 gene encodes the Cu/Zn superoxide dismutase enzyme, which catalyzes the 
inactivation of superoxide into oxygen and hydrogen peroxide, providing antioxidant defense (Smirnoff 
1993). To date, more than 170 mutations have been reported for SOD1 in the Amyotrophic Lateral 
Sclerosis Online Genetics Database (ALSoD Database; Abel et al., 2012) since the gene was firstly 
associated to ALS in 1993 (Rosen et al., 1993). SOD1 mutations occur in all the five exons of the gene.  
Another frequently mutated ALS gene is chromosome 9 open reading frame 72 (C9ORF72), which – in 
addition to the SOD1 mutations – is now recognized as the main cause of familial and sporadic ALS 
(Majounie et al., 2012; Gijselinck et al., 2012; Ratti et al., 2012;  Smith et al., 2013). A hexanucleotide 
(GGGGCC) repeat expansion (RE) located in the non-coding region of the gene that can reach up to 4400 
units (normal range: 2-23 units) has been identified in patients with ALS and/or frontotemporal 
dementia. The GGGGCC RE contributes to 23–47% of familial ALS and to 4–5% of sporadic cases (Renton 
et al., 2011; DeJesus-Hernandez et al., 2011; Byrne et al., 2012; Ratti et al., 2012), with a frequency 
depending on geographical origin. Although the pathomechanism with which the hexanucleotide RE 
leads to the development of ALS has not been elucidated completely, both C9orf72 haploinsufficiency 
gain of function mechanisms (driven by toxicity of sense and antisense RNA transcripts and derived 
dipeptide repeat proteins) have been reported (Taylor et al., 2016). 
In this study, we have investigated the contributions of the two most commonly mutated ALS genes, 
SOD1 and C9ORF72, to the pathogenesis of the disease in Hungarian patients (n=66). This study 
represents the first genetic screening of ALS in Hungary, which adds novel data to the genetic and 
phenotypic diversity of this disease.  
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2. Patients and methods 
 
2.1 Investigated individuals 
 
The unrelated patients (n=66) included in this study were recruited from the Department of Neurology, 
University of Szeged, Szeged, Hungary, between 2010 and 2016. All patients fulfilled the El Escorial 
criteria for ALS (Brooks et al., 2000). Of the 66 cases, only one patient reported other affected family 
members; the other 65 cases were considered sporadic. All patients were of Hungarian ancestry. The 
study was approved by the Internal Ethical Review Board of the University of Szeged. Written informed 
consent was obtained from all patients, and the study was conducted according to the Principles of the 
Declaration of Helsinki. 
 
2.2 Genetic analyses 
 
Blood samples were collected from all the enrolled individuals (n=66), and genomic DNA was isolated 
using a BioRobot EZ1 DSP Workstation (QIAGEN; Godollo, Hungary). The entire coding region of the 
SOD1 gene and the flanking introns were amplified (primer sequences used were taken from the UCSC 
Genome Browser www.genome.ucsc.edu). Direct sequencing of the PCR products was performed on an 
ABI 3100 sequencer and compared with the wild-type gene sequences at the Ensemble Genome Browser 
(http://ensemble.org). To identify known variations, we used ALS Online Genetics Database 
(http://alsod.iop.kcl.ac.uk/) (Abel et al., 2012), 1000 Genomes Database (www.1000genomes.org/), 
dbSNP (http://www.ncbi.nlm.nih.gov/project/SNP) and Exome Aggregation Consortium (ExAC) database 
(http://exac.broadinstitute.org). To predict the functional effects of novel mutations, the sequence 
variations were assessed by in silico prediction programs, such as SIFT (http://sift.bii.a-star.edu.sg/), 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2) and Mutation Taster (http://mutationtaster.org). To 
examine possible effects of the mutations on the three-dimensional (3-D) structure of the SOD1 protein, 
we used the Swiss-Model protein structure homology-modeling server (http://swissmodel.expasy.org/; 
SOD1 Protein Data Bank accession number 4b3e.1.A).   
A two-step protocol was followed for the detection of the GGGGCC hexanucleotide RE in the C9ORF72 
gene. Fragment length analysis was performed using GeneMapper ID v3.2.1., and the samples producing 
a single peak product were further analyzed in the second step by repeat-primed PCR using an 310 ABI 
Prism Genetic Analyzer (Applied Biosystems). The peaks were visualized using GeneMapper ID v3.2.1. 
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software (Akimoto et al., 2014). The presence of the GGGGCC RE was observed as a saw-tooth pattern 
with 6-base pair periodicity.  
To determine whether the single individual carrying the GGGGCC RE identified in this study also carried 
the “risk” haplotype, we selected the rs3849942 variant to be used as a marker for the “risk” haplotype 
for the patient and control genotypes. Rs3849942 genotyping was based on allelic discrimination assays 
using TaqMan chemistry following the manufacturer’s instructions (Life Technologies; Budapest, 
Hungary). 
 
3. Results 
 
The direct DNA sequencing approach identified four different mutations of the SOD1 gene in 5 ALS 
patients: three known heterozygous missense mutations (c.43G>A p.Val14Met; c.272A>C p.Asp90Ala; 
c.435G>C p.Leu144Phe) and one novel mutation (c.275_276delAA, p.Lys91ArgfsTer8) (Table 1).  
The detected novel heterozygous mutation (c.275_276delAA, p.Lys91ArgfsTer8) is located in the fourth 
exon of the SOD1 gene (Figure 1a) and led to a frameshift with the insertion of 8 novel amino acids and 
the formation of premature stop codon at the new amino acid position 99. Analysis using Mutation 
Taster software predicted that the p.Lys91ArgfsTer8 mutation causes severe truncation of the encoded 
enzyme, and, thus, we hypothesize that this mutation is likely to be pathogenic (Figure 1b). The 
pathogenic role of the p.Lys91ArgfsTer8 mutation is further supported by the fact that it interferes with 
the integrity of the Cys57-Cys146 disulfide bond, and results in the weakening of the dimer interface.  
The novel p.Lys91ArgfsTer8 SOD1 mutation was not present in 110 healthy controls of Hungarian 
ancestry that we investigated, neither it is represented in mutation databases, including Single 
Nucleotide Polymorphism Database (http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 Genomes 
(www.1000genomes.org/), Exome Aggregation Consortium (ExAC) database 
(http://exac.broadinstitute.org) and the ALS Online Genetics Database (http://alsod.iop.kcl.ac.uk/) (Abel 
et al., 2012). 
This novel mutation was carried by a female Hungarian patient suffering from sporadic ALS with the 
latest onset but the fastest progression of the disease (Table 1). She had been cured from a breast 
cancer eight years before the onset of ALS and proved to be tumor free on following checkups. As first 
symptoms, the lower extremities became clumsy and weak because of spasticity and muscle atrophy. 
The calculated ALS Functional Rating Scale R (ALSFRS-R score; Cedarbaum et al., 1999) was 39/48 at the 
first examination, which was carried out four months after the appearance of the first symptoms. Then, 
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the signs of upper and lower motor neuron damage developed fast together with bulbar and 
pseudobulbar symptoms. She was given 2x50 mg riluzole/day, nevertheless, her status deteriorated 
quickly, and she became tetraplegic with dysarthria and dysphagia. Respiratory failure developed due to 
the weakened respiratory muscles and she died at home. 
The SOD1 p.Leu144Phe mutation is located in the fifth exon of the gene and was identified in two female 
ALS patients. One of the patients reported that her maternal grandfather had suffered from non-
progressive paralysis and weakness for 20 years. The other patient reported that her paternal 
grandmother had suffered from a disease similar to her own. In this study, only the latter patient was 
therefore considered as having a familial form of the disease. She was the youngest one at the disease 
onset. 
The p.Val14Met mutation is located in the first exon of the SOD1 gene and was present in an affected 
female patient who reported no family history of ALS. Her first symptoms appeared at the age of 62. This 
patient showed lower and upper motor neuron signs. The disease course was progressive and led to the 
patient’s death within one year after disease onset. 
The p.Asp90Ala mutation, which is the most prevalent SOD1 mutation in Europe (Andersen et al., 1995; 
Al-Chalabi et al., 1998; Andersen 2001), is located in the fourth exon of the SOD1 gene and was present 
in a female patient. The patient also carried the rs111273304 splice-donor variant (c.239+2T>A), which is 
of unknown significance, in heterozygous form. This patient had clinical features typically associated with 
this genotype, including a relatively long survival after onset (Andersen 2006).  
Analysis of the C9orf72 gene identified GGGGCC RE in one out of 66 ALS patients. The average repeat 
number based on fragment-length analysis was 5 (range 2–17 repeats) in the remaining 65 patients, 
none of whom carried repeat expansion. The patient with the repeat expansion also carried the 
rs3849942 risk allele, which was previously described as a part of the Finnish “risk” haplotype 
(Laaksovirta et al., 2010). 
This latter patient (Table 1) reported the first symptoms of ALS six months before she presented to the 
neurological unit at age 65 with gradually increasing foot drop on the left side due to peroneal weakness. 
The ALSFRS-R was 44/48. Three years before admission, an adenoma of one of the parathyroid glands 
causing hyperparathyroidism was surgically removed but on admission the level of the parathyroid 
hormone in her serum was within normal ranges. A debate whether hyperparathyroidism can mimic ALS 
has been ongoing for the last 50 years (Jackson et al., 1998). 
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4. Discussion 
 
In this study, we analyzed SOD1 and C9ORF72 genes in a cohort of 66 Hungarian ALS patients, including 
one single case with a reported familial history for the disease. We identified a novel and likely disease-
causing heterozygous frameshift mutation (p.Lys91ArgfsTer8) in the SOD1 gene. Three other 
heterozygous recurrent SOD1 missense mutations (p.Val14Met, p.Asp90Ala and p.Leu144Phe) were also 
detected. SOD1 mutations were detected in 7.5% (5/66) of our cohort, in line with literature data 
reporting that SOD1 mutations account for approximately 0–7% patients with sporadic disease 
(Andersen, 2006). 
The identified novel p.Lys91ArgfsTer8 SOD1 mutation is associated with a typical ALS phenotype 
characterized by lower and upper motor neuron signs. The disease had a late onset at the age of 67 
years and progressive course leading to the death of the patient within one year after the onset of the 
signs and symptoms of the disease. The two-base-pair deletion of the p.Lys91ArgfsTer8 SOD1 mutation 
leads to a frameshift with the formation of a premature stop codon after the insertion of eight novel 
amino acids, causing a severe truncation of the protein (Figure 1b). This truncation abolishes the 
integrity of the intrachain C57–C146 disulfide bridge. Although most mutations in the SOD1 gene are 
missense ones, a few deletions and insertions have been described previously causing truncations of 
different sizes and in most cases affecting also the C57-C146 disulfide bridge (http://alsod.iop.kcl.ac.uk/; 
Abel et al., 2012). The most comprehensively studied truncation mutant is the Gly127insTGGG (G127X), 
carriers of which developed signs of motor neuron degeneration with a rapid disease course (Jonsson et 
al., 2004). These observations correlate well with the clinical manifestations and course of ALS in the 
investigated Hungarian patient with the truncating p.Lys91ArgfsTer8 SOD1 mutation. SOD1 protein with 
truncating mutations exhibits structural instability causing misfolding in the mutated enzyme (Jonsson et 
al., 2004) which can consequently aggregate in motor neurons and lead to the development of ALS 
(Forsberg et al., 2011). 
With the exception of the p.Asp90Ala SOD1 mutation, the detected recurrent mutations are all 
associated with typical ALS phenotypes, characterized by lower and upper motor neuron signs, late onset 
and progressive disease course. In the case of the patient with the p.Asp90Ala heterozygous mutation, 
lower limb involvement and relatively long duration of the disease course was detected similarly to cases 
reported previously (Robberecht et al., 1996; Andersen et al., 2006). The p.Asp90Ala mutation is the 
most common SOD1 mutation in Europe (Andersen 2001), and it can be inherited in either a dominant or 
recessive manner (Robberecht et al., 1996).  
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The p.Leu144Phe missense mutation, which is the most prevalent mutation in the Balkan region (ALSoD), 
was detected in a familial and in a sporadic case. The clinical symptoms and the course of the disease 
were similar in these two patients. To note, the patient with a positive family history developed ALS 
symptoms at a relatively early age, whereas onset for the other patient was late. Although a significant 
number of patients with this mutation have lower limb onset (Corcia et al., 2011), both of our patients 
developed upper and lower motor neuron signs. The rare p.Val14Met mutation was detected in an 
apparently sporadic case in a female patient with upper and lower motor neuron signs. None of the 
SOD1 mutations detected in these ALS patients was identified in 110 healthy Hungarian controls.  
C9orf72 repeat expansion was detected only in one patient of 66. The patient carrying the RE variant 
also carried the previously described rs3849942 risk allele (Laaksovirta et al., 2010; DeJesus-Hernandez 
et al., 2011) in heterozygous form. According to earlier findings, the “A” allele of SNP rs3849942 was 
significantly associated to the expanded C9ORF72 allele (DeJesus-Hernandez et al., 2011). We screened 
110 controls of Hungarian origin to establish the allele frequencies in this genomic position. The allele 
frequency of the minor allele in the Hungarian population (MAF (A) = 0.18) correlates well with the data 
from 1000 Genomes Database (www.1000genomes.org/). We observed that the average repeat number 
was 5 (range: 2–17 repeats) in the remaining 65 patients who did not carry repeat expansions.  
In conclusion, we performed the first genetic analysis of SOD1 and C9ORF72 genes in a cohort of 
Hungarian ALS patients. Our study further widens the geographic range for the origin of disease-causing 
heterozygous missense and frameshift mutations of the SOD1 gene, which have already been implicated 
in ALS patients from different countries of origin. In this study, we identified the hexanucleotide RE of 
the C9ORF72 gene only in one sporadic patient. These results suggest that the frequency of RE observed 
in the Hungarian ALS patients (1,5%) is significantly lower than in Western European populations  
(Majounie et al., 2012; Ratti et al., 2012; Fogh et al., 2014), further demonstrating that the frequency of 
genetic factors for ALS varies among different geographic regions.  
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Figure legends 
 
Figure 1. A novel p.Lys91ArgfsTer8 mutation in the Cu-Zn superoxide dismutase 1 (SOD1) gene identified 
in a Hungarian ALS patient  
(a) The p.Lys91ArgfsTer8 novel frameshift mutation in the SOD1 gene was identified by direct 
sequencing. (b) The crystallographic model shows that the novel frameshift mutation causes a severe 
truncation of the protein.  
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Table 1. Clinical data of Hungarian ALS patients carrying pathogenic variants in SOD1 and C9orf72 genes 
 
Gene 
Age of 
onset/gender Mutation Disease signs 
Disease 
duration, years Other diseases 
ALS family 
history Reference 
SOD1 62/Female p.Val14Met LMN, UMN 1  Lumbar disc protrusions, 
atherosclerosis 
No Deng et al. 1995 
SOD1 63/Female p.Asp90Ala LMN, UMN, B 12  Lumbar disc protrusions No Andersen et al. 1995 
SOD1 67/Female p.Lys91ArgfsTer8 LMN, UMN, B, 
PB 
1  Breast cancer, hypertension, 
hypercholesterolemia, spondylosis and 
lumbar disc protrusions 
No This study 
SOD1 29/Female p.Leu144Phe LMN, UMN 4  None reported Yes Deng et al. 1993 
SOD1 46/Female p.Leu144Phe LMN, UMN, B 3  Lumbar disc protrusions No Deng et al. 1993 
C9orf72 65/Female Repeat Expansion LMN, 
UMN 
0,5  Hyperparathyroidism, multiple lipomas No Renton et al., 2011; 
DeJesus et al.,2011 
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Highlights 
• A novel (K91RfsX8) and three recurrent mutations (V14M, D90A, L144F) were detected  
• The novel K91RfsX8 mutation causes severe truncation of the encoded enzyme 
• The repeat expansion of the C9ORF72 gene was present in one Hungarian patient 
• First genetic analysis of two major ALS causative genes in Hungarian patients. 
 
